Abstract
Statement of Retraction: Adjuvant radiotherapy in patients with diffuse large B-cell lymphoma in advanced stage (III/IV) improves the outcome in the rituximab eraWe, the Editor[s] and Publisher of Hematology, have retracted the following article:Avilès, A, Nambo, M-J, Calva, A, et al. Adjuvant radiotherapy in patients with diffuse large B-cell lymphoma in advanced stage (III/IV) improves the outcome in the rituximab era. Hematology. 2019;24:507–511; DOI:10.1080/10245332.2018.1423880The above article has been retracted as a result of concerns regarding the data upon which the presented research has been based. After re-examination and several independent expert reviews the consensus is that the data and results are not reliable and therefore the article must be retracted. The authors have agreed with this decision.We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
Highlights
Bulky disease was not considered to be an adverse prognostic factor in the International Project Index (IPI) data continue to emerge in the treatment of patients with Diffuse large B-cell lymphoma (DLBCL), which suggested that the benefit of consolidative RT in improving local control, progression-free survival (PFS) and potentially overall survival (OS) [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18]
The criteria to be included in the study include: aged between >18 and
In this cohort of patients with newly diagnosed DLBCL with adverse prognostic factors such as high clinical risks and the presence of nodal bulky disease, we examined the impact of consolidative RT on the outcome among patients who were treated initially with RCHOP, and adding RT or not RT, as consolodation treatment
Summary
Bulky disease was not considered to be an adverse prognostic factor in the International Project Index (IPI) data continue to emerge in the treatment of patients with DLBCL, which suggested that the benefit of consolidative RT in improving local control, progression-free survival (PFS) and potentially overall survival (OS) [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18]. We previously evaluated the efficacy of RT in patients with DLBCL, at higher clinical risks and the presence of bulky nodal disease (nodal tumor mass >10 cm), and show that RT improves PFS and OS; these studies were performed in the pre-rituximab era [19,20]. We examined the effects of consolidative RT in patients who were in complete response (CR) after receiving six cycles of CHOP-R
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
